Introduction
============

Renal cell carcinoma (RCC) accounts for 80--90% of cases of kidney cancer. The incidence rate of RCC is generally higher in more developed countries than in less developed countries ([@b1-ol-06-02-0421]). The rate of RCC is 2-fold higher in males than in females and increases with age. RCC is a pathogenically heterogeneous disease and clear cell RCC (ccRCC) accounts for 70--80% of cases of kidney cancer. Epidemiological studies have identified that hypertension, obesity, cigarette smoking and exposure to trichloroethylene are environmental risk factors of RCC; however, the impact of these factors may vary among populations ([@b2-ol-06-02-0421]--[@b4-ol-06-02-0421]). Environmental factors and their interaction with genetic factors are hypothesized to affect the risk of RCC ([@b5-ol-06-02-0421],[@b6-ol-06-02-0421]). Single nucleotide polymorphisms (SNPs) in cancer growth-related cytokines, including vascular endothelial growth factor, Dickkopf-3 in the Wnt pathway and blood pressure genes, are associated with RCC risk ([@b7-ol-06-02-0421]--[@b9-ol-06-02-0421]). SNPs of metabolic enzymes, including cytochrome P450 mono-oxygenases, N-acetyltransferase and glutathione S-transferase, are associated with RCC risk in Caucasians; although, these correlations have not been replicated in Chinese individuals ([@b4-ol-06-02-0421],[@b10-ol-06-02-0421]), indicating that the association between genetic predisposition and RCC risk alters among various populations. However, a number of studies using candidate-gene approaches have not yielded a conclusive result ([@b4-ol-06-02-0421]--[@b10-ol-06-02-0421]).

Surgical resection remains the curative therapy for RCC patients; although, patients treated surgically have 5- and 10-year relative survival rates of 72 and 63%, respectively ([@b11-ol-06-02-0421]). Previous studies have shown that specific clinical and molecular factors have predictive values for postoperative prognosis: Advanced tumor stages; circulating molecules, including C-reactive protein and erythrocyte polyamines; molecules in the tumor, including L1 cell adhesion molecules; and chromosomal variations, including 10q and 13q deletions, and D9S168 micro-satellite alterations. These factors are capable of predicting a poor postoperative prognosis for RCC ([@b12-ol-06-02-0421]--[@b16-ol-06-02-0421]). Genetic predispositions, including the Dickkopf-2 rs17037102 polymorphism, interleukin-4 haplotype -589T-33T, *MDM2* rs2279744 polymorphism and miRNA-related genetic polymorphisms are closely associated with RCC clinical outcome ([@b8-ol-06-02-0421],[@b17-ol-06-02-0421]--[@b19-ol-06-02-0421]).

A previous genome-wide association study (GWAS) in RCC cases and controls of European background revealed that two loci mapped to *EPAS1,* encoding hypoxia inducible factor (HIF)-2α, on 2p21 (rs11894252 and rs7579899), a locus on 11q13.3 (rs7105934) and a locus mapped to *SCARB1,* encoding the scavenger receptor class B, member 1, on 12q24.31 (rs4765623) were significantly associated with RCC susceptibility ([@b20-ol-06-02-0421]). rs7105934 at 11q13.3 was detected to modulate the binding and function of HIF-2α at a transcriptional enhancer of *CCND1* (encoding cyclin D1) ([@b21-ol-06-02-0421]). In the present study, the correlations between SNPs identified in the present GWAS and RCC susceptibility were validated, and the role of SNPs in the postoperative prognosis of RCC was investigated in a Chinese population.

Materials and methods
=====================

Study subjects
--------------

A total of 400 pathologically confirmed, sporadic RCC patients diagnosed between November 1998 and November 2011 at the Department of Urology (Changhai Hospital, Second Military Medical University, Shanghai, China) were involved in the present study. In addition, 806 controls that received comprehensive physical examinations, including type-B ultrasonic and blood tests, and were confirmed to be healthy at the Physical Examination Center of Changhai Hospital between 2006 and 2011, were also involved. Individuals who did not have notable metastasis at the time of surgery and did not receive adjuvant therapy after surgery were followed up. Follow-up was initiated 6 months after surgery, performed by telephone or interviews in person at the Outpatient Department every 3 months, in accordance with standard epidemiological procedures. The median follow-up period was 34.0 months (range, 3.0--90.9 months). All participants were of Chinese ethnic origin, and the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Institutional Review Board of the Second Military Medical University (Shanghai, China). All participants provided written informed consent.

Genotyping of genetic polymorphisms
-----------------------------------

Genomic DNA was extracted from blood samples using QIAquick PCR purification kits (Qiagen, Hilden, Germany). rs4765623, rs7105934, rs7579899 and rs1867785 (highly correlated with rs11894252) were genotyped using fluorescent-probe qPCR in a LightCycler^™^ 480 (Roche Diagnostics, Mannheim, Germany). Primers and probes (TaqMan or Minor Groove Binder) were designed and synthesized by GeneCore BioTechnologies Co., Ltd. (Shanghai, China), and the sequences of the primers and probes are shown in [Table I](#t1-ol-06-02-0421){ref-type="table"}. Each reaction mixture contained 0.2 *μ*mol/l primers and probes, as well as 0.1--0.5 *μ*g purified templates in the Premix Ex Taq^™^ reaction system (Takara Bio, Inc., Shiga, Japan). Three duplicative samples were run with a template-free control.

Western blotting
----------------

Protein was extracted from the adjacent renal tissue of fresh RCC specimens and quantified using cell lysis buffer and Enhanced BCA Protein Assay kits (Beyotime Institute of Biotechnology, Jiangsu, China). Extracted proteins were resolved by routine PAGE gels and transferred onto polyvinylidene difluoride membranes. The membranes were incubated overnight with rabbit monoclonal antibodies against cyclin D1 (1:1,000; Epitomics Inc., Burlingame, CA, USA) and β-ctin (1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA), washed and incubated with HRP-conjugated anti-rabbit or anti-mouse IgG (Cell Signaling Technology, Inc.) for 2 h. Peroxidase activity was developed by ECL detection reagent (GE Healthcare, Amersham, UK) according to the manufacturer's instructions. The signal intensity of each band was quantified using Genetools software, version 4.02 (Syngene, Cambridge, UK). The relative intensity of each sample was calculated as the intensity of the cyclin D1 band (raw value-background noise)/the intensity of the β-actin band (raw value-background noise).

Immunohistochemistry
--------------------

Antibodies against cyclin D1 (1:100) were used for immunohistochemistry of RCC specimens in accordance with methods previously described for western blotting ([@b22-ol-06-02-0421]). Sections were independently assessed by four researchers who were blinded to the clinical information. Immunostaining intensity was scored as follows: Negative (−), \<5% positive cancer cells; weak (+), 5--20% positive; moderate (++), 20--60% positive; and strong (+++), \>60% positive. There was \>95% agreement among the researchers and disagreements were resolved by consensus. A total of 90 paraffin-embedded samples were used in immunohistochemical assay.

Statistical analysis
--------------------

Differences in categorical variables were evaluated using the χ^2^ test. Hardy-Weinberg equilibrium (HWE) was examined online (<http://ihg.gsf.de/ihg/snps.html>) and linkage disequilibrium (LD) analyses for the SNPs involved in the current study and those identified in previous GWAS ([@b23-ol-06-02-0421],[@b24-ol-06-02-0421]) were performed using online Haploview 4.2 software (<http://hapmap.ncbi.nlm.nih.gov>). Differences in the relative intensities of the western blotting bands among the samples of various genotypes were analyzed using the Student's t-test. Unconditional logistic regression analysis was used to obtain an odds ratio (OR) for each SNP with RCC and a 95% confidence interval (CI). Overall survival was analyzed using the Kaplan-Meier method and the log-rank test was used to compare survival curves. Forward stepwise multivariate Cox regression analysis (P~entry~=0.05 and P~removal~=0.10) was performed to determine the factors contributing independently to RCC prognosis. The correlation between immunostaining scores for cyclin D1 and RCC stage and the rs7105934 genotypes was determined by Spearman's rank correlation analysis, respectively. All statistical tests were two-sided and conducted using SPSS for Windows, version 16.0 (SPSS, Inc., Chicago, IL, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Correlation between the four SNPs and RCC risk
----------------------------------------------

[Table II](#t2-ol-06-02-0421){ref-type="table"} shows the characteristics of the RCC patients and healthy controls from the present study. The gender distribution was not significantly different between the RCC patients and healthy controls; however, the healthy controls were significantly older than the RCC patients (median ± standard deviation; 60.1±12.8 vs. 57.1±12.8 years; P\<0.001). The genotyping call rate was 100% for each SNP, and in the healthy controls, rs4765623, rs7105934, rs7579899 and rs1867785 conformed to HWE (P=0.481, 0.891, 0.352 and 0.373, respectively). LD analysis indicated that rs7579899 was markedly correlated with rs1867785 (r^2^=0.988 in this study population), whereas rs1867785 was not in LD with rs12617313 or rs9679290 (r^2^\<0.05 in the HapMap Chinese population), the SNPs identified on chromosome 2p21 by a previous GWAS ([@b24-ol-06-02-0421]). [Table III](#t3-ol-06-02-0421){ref-type="table"} shows the correlation between the SNPs and RCC risk. Of the four SNPs, rs7105934 only was found to significantly correlate with RCC risk. The dominant model or A allele at rs7105934 was significantly correlated with a reduced risk of RCC following adjustments for age and gender, with a power of 77.4%. As ccRCC is the major histological type, the correlation between the four SNPs and ccRCC risk was examined, and rs7105934 only was found to correlate with the risk of ccRCC. Compared with the GG genotype, the GA + AA genotype of rs7105934 was significantly correlated with a reduced ccRCC risk with an OR of 0.60 (95% CI, 0.40--0.92; P= 0.018), following adjustments for age and gender. By contrast, the A allele of rs7105934 was inversely associated with ccRCC risk following adjustments (OR, 0.62; 95% CI, 0.41--0.92; P=0.018).

Correlation between SNPs and RCC prognosis
------------------------------------------

Of the RCC patients, 194/400 completed the follow-up and were included in the survival analysis. It was identified that rs7105934 GA + AA genotype was significantly correlated with an improved postoperative prognosis of RCC (P=0.046; Kaplan-Meier and log-rank test; [Fig. 1A](#f1-ol-06-02-0421){ref-type="fig"}). [Table IV](#t4-ol-06-02-0421){ref-type="table"} presents the results of stepwise multivariate Cox regression analysis, indicating that patients with the rs7105934 GA + AA genotype have a decreased risk of mortality (HR, 0.12; 95% CI, 0.016--0.93; P=0.042). In addition, advanced tumor stage was also found to independently predict poor survival rates in RCC.

Correlation between rs7105934 genotypes and cyclin D1 expression
----------------------------------------------------------------

Expression of cyclin D1 protein in the adjacent renal tissue of fresh RCC specimens was examined using western blotting. No significant differences were identified in the relative intensity of cyclin D1 protein between patients with the GG genotype and those with the GA + AA genotype of rs7105934 (P=0.514; [Fig. 2A](#f2-ol-06-02-0421){ref-type="fig"}). Cyclin D1 expression in the tumors was examined using immunohistochemistry ([Fig. 2B](#f2-ol-06-02-0421){ref-type="fig"}). Immunostaining intensities of cyclin D1 in the cancer cells of the RCC patient specimens did not correlate significantly among the three genotype groups of rs7105934 (P=0.844) or the GG and GA + AA genotypes of rs7105934 (P=0.884). However, immunostaining intensities of cyclin D1 in the cancer cells was inversely correlated with advanced tumor stage (P=0.046; Spearman's correlation coefficient, −0.211; [Table V](#t5-ol-06-02-0421){ref-type="table"}).

Correlation between cyclin D1 expression in cancer cells and RCC prognosis
--------------------------------------------------------------------------

The association between cyclin D1 expression in cancer cells and RCC prognosis was first evaluated using Kaplan-Meier analysis. Moderate to high expression (++/+++) of cyclin D1 in cancer cells predicted an improved postoperative prognosis of RCC when compared with that of negative or weak expression (−/+) (P=0.015; Kaplan-Meier analysis and the log-rank test; [Fig. 1B](#f1-ol-06-02-0421){ref-type="fig"}). Multivariate Cox regression analysis indicated that moderate and high expression (++/+++) of cyclin D1 in cancer cells independently predicted an improved postoperative prognosis (HR, 0.13; 95% CI, 0.02--0.96; P=0.045).

Discussion
==========

In the present study, the correlation between four SNPs identified in a previous GWAS study of a European population and the development and prognosis of RCC in a Chinese population was investigated. In the current study, the healthy controls and RCC patients were matched by gender, but the healthy controls were significantly older than the RCC patients. This age contrast may have prevented misclassification bias, as RCC incidence increases with age ([@b2-ol-06-02-0421]). The current study identified that, of the four SNPs validated, only rs7105934 significantly correlated with the risk of RCC, particularly ccRCC, in the Chinese population. An additional study investigating the association between rs7579899, rs7105934 and rs4765623 and RCC risk in an additional group of Chinese individuals has been reported ([@b25-ol-06-02-0421]). Similar to the results of the current study, the study identified that only rs7105934 of the genotyped SNPs correlated with a reduced risk of RCC. Therefore, genetic predisposition of RCC appears to differ between the two ethnic groups and rs7105934 may confer genetic susceptibility to RCC in a number of populations.

An important observation of the present study was that the rs7105934 GA + AA genotype is an independent factor for improved RCC prognosis, with an HR of 0.12 (95% CI, 0.02--0.93), in contrast to advanced tumor stage. The genetic risk factor of RCC development may also modulate RCC outcome. rs7105934 is situated at a transcriptional enhancer ∼220-kb telomeric to the cyclin D1 encoding gene, *CCND1* ([@b20-ol-06-02-0421]). SNPs 5-kb centromeric to rs7105934 modulate the binding and function of HIF-2α at the enhancer for *CCND1.* The minor (RCC-protective) allele at 11q13.3 disrupts HIF binding, DNA accessibility and interaction with the transcriptional apparatus at the *CCND1* enhancer, and alters the allelic balance of *CCND1* gene expression ([@b21-ol-06-02-0421]). The rs7105934 GA genotype appears to be associated with lower levels of *CCND1* mRNA in adjacent renal tissue when compared with that of the GG genotype ([@b25-ol-06-02-0421]). Therefore, the correlation between the GA + AA genotype and an improved prognosis of RCC may be caused by low expression of cyclin D1 in tumors. Of note, the present study identified that moderate to high expression of cyclin D1 is an independent predictor of an improved postoperative prognosis in RCC. No significant differences were identified in cyclin D1 protein expression between specimens with the GG genotype and those with the GA + AA genotype in adjacent renal tissue and in the tumor tissue. In addition, the intensity of cyclin D1 immunostaining did not correlate with the rs7105934 genotype, and these results were not consistent with the hypothesized involvement of rs7105934 genotypes in cyclin D1 expression in RCCs. Thus, cyclin D1 and the rs7105934 SNP may both be significant in the carcinogenesis and postoperative prognosis of RCC, but function independently. Further studies are required to validate and investigate the correlation between rs7105934 genotypes and the expression of cyclin D1 and other candidate target proteins in RCCs.

In the present study, cyclin D1 expression in RCC cells was confirmed to inversely correlate with advanced stages of RCC and represent an independent predictor of improved prognosis of RCC. The results of the current study are similar to those of previous studies reporting that high cyclin D1 expression significantly correlates with an improved prognosis, while low expression of cyclin D1 correlates with a poor prognosis of ccRCC ([@b26-ol-06-02-0421]--[@b28-ol-06-02-0421]). The expression of cyclin D1 is markedly correlated with that of p27 in ccRCC; low p27 expression independently predicts a poor prognosis of RCC, whilst low cyclin D1 expression appears to shorten the survival rate of RCC patients ([@b29-ol-06-02-0421]). These differences may reflect variations in the cyclin D1-related cell biology of various cancer types. Cyclin D1 is an oncoprotein that activates the G~1~-S transition of the cell cycle and functions as a downstream effector of β-catenin signaling. Downregulation of β-catenin expression may contribute to the malignant character of RCC and result in tumor progression ([@b30-ol-06-02-0421]). Cyclin D1 is upregulated in primary ccRCCs, which may contribute to cell proliferation in primary RCCs, and its importance may diminish at later stages of RCC progression due to specific complex mechanisms, including epithelial-mesenchymal transition.

Several limitations of the present study must be noted: i) follow-up information was only available for 194 study subjects and the majority of individuals without follow-up information were from other provinces of China, which made regular contact difficult; ii) patients were excluded in cases where postoperative therapy was administered, including interferon-α and interleukin-2 treatments, during the follow-up period; iii) epidemiological studies of specific risk factors, including smoking and alcohol consumption, were incomplete and thus not included in the analysis, resulting in loss of data; and iv) SNPs were validated from only one GWAS study ([@b20-ol-06-02-0421]) and novel RCC-related SNPs on 12p11.23 and 2p21 ([@b23-ol-06-02-0421],[@b24-ol-06-02-0421]) require validation, as these SNPs are not in LD with the four SNPs validated for the present study.

Overall, the present study showed that, of the four RCC-related SNPs identified in a European population, only rs7105934 correlated with RCC risk in a Chinese population. The GA + AA genotype was significantly correlated with reduced risk and an improved postoperative prognosis of RCC. Therefore, rs7105934 may confer genetic susceptibility to RCC in extended populations. No significant differences were identified in the levels of cyclin D1 expression in adjacent renal tissue and RCC cells between patients with the rs7105934 GG genotype and those with the GA + AA genotype. Cyclin D1 expression in RCC cells was inversely correlated with advanced stages of RCC. In addition, moderate to high expression of cyclin D1 was an independent predictor of improved postoperative prognosis of RCC. However, the results do not support the hypothesis that rs7105934 genotypes are involved in the expression of cyclin D1 in the kidneys. Cyclin D1 and the rs7105934 SNP may represent significant factors in RCC, however, their effects appear to be independent. Although validation of these observations is required in independent populations, the current study highlights a novel genetic marker that is capable of predicting the postoperative prognosis of RCC.
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![Correlation between rs7105934 or cyclin D1 protein expression in tumor tissues and overall survival of RCC patients following curative nephrectomy (Kaplan-Meier analysis and log-rank test). (A) rs7105934 and overall survival (n=194). (B) Cyclin D1 protein expression in tumor tissues and overall survival (n=90). −, negative (\<5% positive cancer cells); +, weak (5--20% positive); ++, moderate (20--60% positive); +++, strong (\>60% positive); RCC, renal cell carcinoma.](OL-06-02-0421-g00){#f1-ol-06-02-0421}
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###### 

Primers and probes for genotyping the four single nucleotide polymorphisms.

                                 Variation                               Primers 5′-3′               Probes
  ------------------------------ --------------------------------------- --------------------------- ---------------------------------------
  rs7105934                      G/A                                     GAGGAATGATGAACAAACTGTGGTA   FAM-CCAAAATGCATCGTGCTAAGAAGCC-TAMRA
  CAGAACATCACATAAATGGAATCATACA   HEX-TCCAAAATGCATCATGCTAAGAAGCC-TAMRA                                
  rs1867785                      A/G                                     GGACTTCTCTCTCCCTTCACCCT     FAM-AAATTAGCTTCGTTGACCTCAGCCAGC-TAMRA
  TCCTGTGTTTCCAAGAGTTCTCAGA      HEX-ATTAGCTTCGTCGACCTCAGCCAGC-TAMRA                                 
  rs7579899                      A/G                                     ACACAGCCAAATCCAAGTCAGA      FAM-ACACCCTGTACAAAGCACTGCGACC-TAMRA
  TGACCAAACACTAGGAAAGGAGAAG      HEX-ACACCCTGTACAGAGCACTGCGACC-TAMRA                                 
  rs4765623                      C/T                                     GGTCTCGCGCATGTGTCA          FAM- AGTACAGCCACCTCGGAGAGCCACT-TAMRA
  CCAGATGCGTTCAGCAGTTC           HEX- AGTACAGCCACCTTGGAGAGCCACTG-TAMRA                               

###### 

Demographic and clinicopathological characteristics of the study subjects.

  Characteristics     Cases, n (%)   Controls, n (%)   P-value
  ------------------- -------------- ----------------- ---------
  Age, years                                           
    ≤40               31 (7.8)       36 (4.5)          0.008
    40--60            210 (52.5)     380 (47.1)        
    60--80            147 (36.8)     352 (43.7)        
    \>80              12 (3.0)       38 (4.7)          
  Gender                                               
    Male              274 (68.5)     548 (68.0)        0.858
    Female            126 (31.5)     258 (32.0)        
  Histology                                            
    Clear cell        373 (93.3)     \-                
    Papillary         12 (3.0)       \-                
    Chromophobe       8 (2.0)        \-                
    Unclassified      7 (1.8)        \-                
  AJCC (2002) stage                                    
    I                 324 (81.0)     \-                
    II                33 (8.3)       \-                
    III               43 (10.8)      \-                

AJCC, American Joint Committee on Cancer.

###### 

Correlation between the four SNPs and risk of RCC following adjustment for age and gender.

  Genotype     Cases, n (%)   Controls, n (%)   OR (95% CI)         P-value[^a^](#tfn2-ol-06-02-0421){ref-type="table-fn"}
  ------------ -------------- ----------------- ------------------- --------------------------------------------------------
  rs7105934                                                         
    GG         364 (91.0)     700 (86.8)        1.00 (reference)    
    GA         35 (8.8)       102 (12.7)        0.65 (0.43--0.97)   0.036
    AA         1 (0.3)        4 (0.5)           0.47 (0.05--4.25)   0.500
    GG         364 (91.0)     700 (86.8)        1.00 (reference)    
    GA + AA    36 (9.0)       106 (13.2)        0.64 (0.43--0.96)   0.029
    G allele   763 (95.4)     1502 (93.2)       1.00 (reference)    
    A allele   37 (4.6)       110 (6.8)         0.65 (0.44--0.95)   0.028
  rs1867785                                                         
    AA         288 (72.0)     561 (69.6)        1.00 (reference)    
    AG         105 (26.3)     227 (28.2)        0.90 (0.69--1.19)   0.472
    GG         7 (1.8)        18 (2.2)          0.76 (0.31--1.86)   0.552
    AA         288 (72.0)     561 (69.6)        1.00 (reference)    
    AG + GG    112 (28.0)     245 (30.4)        0.89 (0.69--1.17)   0.411
    A allele   681 (85.1)     1349 (83.7)       1.00 (reference)    
    G allele   119 (14.9)     263 (16.3)        0.90 (0.71--1.14)   0.381
  rs7579899                                                         
    AA         287 (71.8)     560 (69.5)        1.00 (reference)    
    AG         106 (26.5)     228 (28.3)        0.91 (0.69--1.19)   0.495
    GG         7 (1.8)        18 (2.2)          0.76 (0.31--1.86)   0.554
    AA         287 (71.8)     560 (69.5)        1.00 (reference)    
    AG + GG    113 (28.3)     246 (30.5)        0.90 (0.69--1.17)   0.432
    A allele   680 (85.0)     1348 (83.6)       1.00 (reference)    
    G allele   120 (15.0)     264 (16.4)        0.90 (0.71--1.14)   0.399
  rs4765623                                                         
    CC         136 (34.0)     268 (33.3)        1.00 (reference)    
    CT         188 (47.0)     385 (47.8)        0.97 (0.74--1.28)   0.845
    TT         76 (19.0)      153 (19.0)        0.97 (0.68--1.37)   0.844
    CC         136 (34.0)     268 (33.3)        1.00 (reference)    
    CT + TT    264 (66.0)     538 (66.7)        0.97 (0.75--1.25)   0.822
    C allele   460 (57.5)     921 (57.1)        1.00 (reference)    
    T allele   340 (42.5)     691 (42.9)        0.98 (0.83--1.17)   0.826

P-values were compared with the corresponding reference. SNPs, single nucleotide polymorphisms; RCC, renal cell carcinoma; OR, odds ratio.

###### 

Factors independently associated with overall survival of RCC patients in stepwise multivariate Cox regression analysis.

                      Cases evaluated, n   Cases of RCC mortality, n   HR (95% CI)           P-value
  ------------------- -------------------- --------------------------- --------------------- ---------
  rs7105934                                                                                  
    GG                172                  25                          1.00 (reference)      
    GA + AA           22                   1                           0.12 (0.016--0.93)    0.042
  AJCC (2002) stage                                                                          
    I                 147                  7                           1.00 (reference)      
    II                12                   3                           5.79 (1.47--22.82)    0.012
    III               35                   16                          15.72 (6.36--38.84)   \<0.001

RCC, renal cell carcinoma; HR, hazard ratio; AJCC, American Joint Committee on Cancer.

###### 

Correlation between rs7105934 genotypes or AJCC stage and cyclin D1 expression in ccRCC specimens.

                      Cyclin D1 expression   P-value   r~s~[^a^](#tfn4-ol-06-02-0421){ref-type="table-fn"}           
  ------------------- ---------------------- --------- ----------------------------------------------------- ------- --------
  rs7105934                                                                                                          
    GG                24                     25        27                                                    0.844   0.021
    GA                5                      3         5                                                             
    AA                0                      0         1                                                             
    GG                24                     25        27                                                    0.884   0.016
    GA + AA           5                      3         6                                                             
  AJCC (2002) stage                                                                                                  
    I                 16                     15        26                                                    0.046   −0.211
    II                3                      3         2                                                             
    III               10                     10        5                                                             

Spearman's correlation coefficient. AJCC, American Joint Committee on Cancer; −, negative (\<5% positive cancer cells); +, weak (5--20% positive); ++, moderate (20--60% positive); +++, strong (\>60% positive); ccRCC, clear cell renal cell carcinoma.
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